Intelligent Pharmacy最新文献_第10页

Omicron variant raises global concerns: Increased hospitalization and India's vaccination advantage 欧米克隆变异引起全球关注:住院人数增加和印度疫苗接种优势

Intelligent Pharmacy Pub Date : 2023-09-02 DOI: 10.1016/j.ipha.2023.08.010

Azhagu Madhavan Sivalingam , Arjun Pandian

{"title":"Omicron variant raises global concerns: Increased hospitalization and India's vaccination advantage","authors":"Azhagu Madhavan Sivalingam , Arjun Pandian","doi":"10.1016/j.ipha.2023.08.010","DOIUrl":"10.1016/j.ipha.2023.08.010","url":null,"abstract":"<div><p>The newly identified COVID-19 variant, B.1.1.529, initially detected in South Africa, was officially designated as the “Omicron” variant by the World Health Organization on November 26, 2021. This variant has raised concerns globally. From January 17 to November 26, 2021, Public Health Ontario (PHO) Library Services conducted extensive searches of published literature and preprints using the MEDLINE database. A total of six articles and one ongoing clinical trial were identified. Data from 15 published and unpublished reports, including interim findings, were collected. The WHO, ICMR, daily updates web page, internet sources, news, and hospitalization or death data were analyzed to assess the risk associated with the Omicron variant compared to non-hospitalized COVID-19 patients. The data suggested a potential 50% increase in the risk of hospitalization or death among Omicron patients compared to previous variants. Considering the emergence of the Omicron variant, it is important to note that India has an advantage due to its extensive immunization program, which annually vaccinates approximately 2.7 crorenewborns. However, it is crucial to ensure that vaccines meet all validation requirements and regulatory frameworks before they are made available to the public.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000692/pdfft?md5=f2f7c96360f808908d1ca0045afa2c34&pid=1-s2.0-S2949866X23000692-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78698269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endovascular thrombectomy and intravenous alteplase for acute ischaemic stroke 血管内血栓切除联合阿替普酶治疗急性缺血性脑卒中

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.04.011

Zhuoling An

引用次数: 0

Exploring the molecular mechanism of Huangqin-Jinyinhua couplet medicines for the treatment of hand-foot and mouth disease using network pharmacology, molecular docking and bioinformatics databases 运用网络药理学、分子对接和生物信息学数据库探讨黄芩金银花联药治疗手足口病的分子机制

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.04.007

Tianyi Liu , Bin Xin , Qi Zhang , Tingyu Li , Yang Liu , Lujuan Li , Zhong Li

{"title":"Exploring the molecular mechanism of Huangqin-Jinyinhua couplet medicines for the treatment of hand-foot and mouth disease using network pharmacology, molecular docking and bioinformatics databases","authors":"Tianyi Liu , Bin Xin , Qi Zhang , Tingyu Li , Yang Liu , Lujuan Li , Zhong Li","doi":"10.1016/j.ipha.2023.04.007","DOIUrl":"https://doi.org/10.1016/j.ipha.2023.04.007","url":null,"abstract":"<div><h3>Background</h3><p>Huangqin-Jinyinhua couplet medicines (HQJYH) were often used to treat hand-foot and mouth disease (HFMD), although its mechanism remains unclear. This study investigated the active ingredients in HQJYH and their mechanism when treating HFMD by network pharmacology and molecular docking.</p></div><div><h3>Methods</h3><p>The TCMSP database obtained the principal active ingredients found in HQJYH. The GeneCards, CTD, PharmGkb and DisGeNet databases were used to obtain the main targets involved in HFMD, and the merged targets were obtained by R software and the Venn package. The DAVID database performed GO and KEGG enrichment analyses on the intersection targets. We also used Cytoscape software to construct an “HQJYH-Active Ingredients-Targets” network and used the STRING platform to conduct protein–protein interaction (PPI) analyses on the intersection targets. Molecular docking of core active ingredients-core targets interactions were modeled using AutoDock Vina software.</p></div><div><h3>Results</h3><p>56 active ingredients were found in HQJYH, corresponding to 212 targets, 5323 HFMD targets, and 156 intersection targets. KEGG enrichment analysis found that genes were mainly enriched in the PI3K-Akt signaling pathway, MAPK signaling pathway and other pathways. Cytoscape showed that the core active ingredients were quercetin, luteolin, kaempferol, beta-sitosterol, stigmasterol, wogonin, baicalein and acacetin. The PPI network showed that the core targets involved were TP53, CASP3, AKT1, IL6, MAPK14, EGFR, and HIF1A. The molecular docking results indicated key binding activity between Baicalein-AKT1, quercetin-AKT1, wogonin-AKT1, kaempferol-AKT and wogonin-MAPK14.</p></div><div><h3>Conclusion</h3><p>This study was based on network pharmacology and revealed the potential molecular mechanisms involved in treating HFMD by HQJYH.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50194981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardioprotective potential of Rosuvastatin against isoproterenol induced cardiac dysfunction and hypertrophy in the experimental model of rodents 瑞舒伐他汀对异丙肾上腺素诱导的啮齿动物心功能障碍和肥厚的保护作用

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.09.002

Rufaida Wasim, Tarique Mahmood, Mohammed Haris Siddiqui, Aditya Singh, Farogh Ahsan

{"title":"Cardioprotective potential of Rosuvastatin against isoproterenol induced cardiac dysfunction and hypertrophy in the experimental model of rodents","authors":"Rufaida Wasim, Tarique Mahmood, Mohammed Haris Siddiqui, Aditya Singh, Farogh Ahsan","doi":"10.1016/j.ipha.2023.09.002","DOIUrl":"https://doi.org/10.1016/j.ipha.2023.09.002","url":null,"abstract":"Cardiovascular disease is the primary cause of mortality and morbidity, and its terminal phase is chronic heart failure. The present study aimed to examine the protective impact of rosuvastatin on isoproterenol-induced chronic heart failure and investigate plausible related mechanisms. Rosuvastatin, a drug with multiple pleiotropic properties, has been examined for its cardioprotective effects in heart failure induced by isoproterenol. Male Sprague Dawley rats were given isoproterenol 5 mg/kg once a day for 7 days to establish heart failure by subcutaneous injection. Simultaneously, rosuvastatin (10 mg/kg) was orally administrated from day 1 to day 14. Protective effects were evaluated by heart grading and gross morphology, hemodynamic parameter, cardiac troponin I, heart mitochondrial enzyme and lysosomal hydrolases and pro inflammatory cytokines levels were analyzed. Rosuvastatin (10 mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of the ventricle, reduced the heart mitochondrial enzyme and lysosomal hydrolases and normalized the increased hemodynamic and pro inflammatory cytokines levels. The study highlights the preventive effects of, rosuvastatin, against heart failure. The results of the research indicate that rosuvastatin has cardioprotective effects on the experimental model, which were supported by several characteristics. However, further research is required to identify the precise molecular mechanisms and signalling pathways of rosuvastatin's impact on heart failure.","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135346682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of olaparib treatment for metastatic castration-resistant prostate cancer with BRCA 1/2 mutations following a new hormonal agent in China 奥拉帕尼治疗新激素制剂后BRCA 1/2突变的转移性去势耐药前列腺癌症的成本-效果分析

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.05.001

Poucheok Pang , Baoying Tan , Jianwei Xuan

{"title":"Cost-effectiveness analysis of olaparib treatment for metastatic castration-resistant prostate cancer with BRCA 1/2 mutations following a new hormonal agent in China","authors":"Poucheok Pang , Baoying Tan , Jianwei Xuan","doi":"10.1016/j.ipha.2023.05.001","DOIUrl":"https://doi.org/10.1016/j.ipha.2023.05.001","url":null,"abstract":"<div><h3>Background</h3><p>The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, olaparib has been approved for the treatment of mCRPC in patients with BRCA1/2 mutations who have progressed following prior therapy that included a new hormonal agents. Patients with prostate cancer carrying BRCA gene mutations exhibit a more aggressive disease progression and poorer prognosis, posing challenges for the effectiveness of current treatment options.</p></div><div><h3>Methods</h3><p>From the perspective of healthcare payers in China, a three-state partition survival model (progression-free survival, progressed disease and death) was constructed to conduct a cost-effectiveness analysis of olaparib versus enzalutamide for the approved indication. The efficacy and safety of olaparib and enzalutamide were obtained from PROfound trial. Cost were from pricing records and the literature. The model was simulated for 10 years with monthly cycles. Costs and health outcomes were discounted by 5%. Sensitivity analyses were conducted to evaluate the robustness of parameters on the results.</p></div><div><h3>Results</h3><p>In the base-case analysis, the total cost of olaparib was ¥ 101,012, with a total of 1.1576 QALYs gained. The total cost of enzalutamide was ¥ 52,425, with a total of 0.5929 QALYs gained. Compared to enzalutamide, olaparib had an ICER of ¥ 86,043 per QALY, with an increase in total costs of ¥ 48,587 and an increase in QALYs of 0.5647. At a threshold of three times per capita GDP of China (¥ 257,094 in 2022), the probability of olaparib being cost-effective compared to enzalutamide was 99.0%.</p></div><div><h3>Conclusion</h3><p>From the healthcare payer perspective, olaparib is cost-effective compared to enzalutamide for the treatment of metastatic castration-resistant prostate cancer in patients with BRCA1/2 mutations who have progressed following prior therapy that included a new hormonal agent.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50194954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research and development of antibody-based novel anti-cancer drugs: An overview 基于抗体的新型抗癌药物的研究与开发综述

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.05.004

Junxiang Zhou , Han Deng , Hongtao Xiao

引用次数: 0

Organ mimicking technologies and their applications in drug discovery 器官模拟技术及其在药物发现中的应用

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.05.003

Yueyang Qu , Jiaming Ye , Bingcheng Lin , Yong Luo , Xiuli Zhang

引用次数: 0

Network pharmacological study of Banxia-Chenpi in the treatment of cough variant asthma in children with phlegm evil accumulation lung syndrome 半夏陈皮治疗小儿痰邪积肺证咳嗽变异性哮喘的网络药理学研究

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.04.004

Bin Xin , Tianyi Liu , Yue Wu , Qingyang Hu , Xue Dong , Huanhuan Wang , Zhong Li

{"title":"Network pharmacological study of Banxia-Chenpi in the treatment of cough variant asthma in children with phlegm evil accumulation lung syndrome","authors":"Bin Xin , Tianyi Liu , Yue Wu , Qingyang Hu , Xue Dong , Huanhuan Wang , Zhong Li","doi":"10.1016/j.ipha.2023.04.004","DOIUrl":"https://doi.org/10.1016/j.ipha.2023.04.004","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the molecular mechanism of Banxia -Chenpi in the treatment of cough variant asthma with phlegm evil accumulation lung syndrome based on network pharmacology and molecular docking technology.</p></div><div><h3>Methods</h3><p>TCMSP database was used to screen the active ingredients and targets of Banxia-Chenpi. GeneCards, OMIM and PharmGKB databases were used to obtain the targets of cough variant asthma. Cytoscape 3.9.1 software was used to construct the “couplet medicines-active ingredients-targets” network and screen key ingredients according to the degree value. The protein–protein interaction data were obtained from the STRING database and core targets were screened by Cytoscape plugin cytoNCA. The core targets conduct GO and KEGG pathway enrichment analyses in the David database. Molecular docking technology was used to verify the binding energy between key ingredients and core targets.</p></div><div><h3>Results</h3><p>There were 16 active ingredients and potential 118 targets in Banxia-Chenpi,2429 cough variant asthma targets, and 72 intersection targets. The key ingredients of the Banxia-Chenpi in treating cough variant asthma were nobiletin, baicalein, naringenin, stigmasterol, beta-sitosterol and coniferin. The core targets of the Banxia-Chenpi for CVA treatment were FOS, MMP9, AKT1, CASP3, TP53, JUN and VEGFA. The molecular docking results indicated key ingredients and core targets of the Banxia-Chenpi in CVA treatment had a good binding affinity.</p></div><div><h3>Conclusion</h3><p>Active ingredients maybe act on MMP9, AKT1, VEGFR and FOS to reduce eosinophils and neutrophils accumulation, dissolve phlegm, alleviate airway inflammation, and reduce airway resistance and hyperresponsiveness for treating CVA. This study provides a reference for clinical medication and subsequent research.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50194982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of epigenetic in cardiovascular diseases: An out and out check 表观遗传在心血管疾病中的作用:彻底的检查

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.09.001

Rufaida Wasim, Tarique Mahmood, Mohammed Haris Siddiqui, Aditya Singh, Asad Ahmad, Farogh Ahsan

引用次数: 0

Clinical application of the neonatal early-onset sepsis risk assessment calculator 新生儿早发性败血症风险评估计算器的临床应用

Intelligent Pharmacy Pub Date : 2023-09-01 DOI: 10.1016/j.ipha.2023.04.015

Tingyu Li, Tianyi Liu, Lujuan Li, Yang Liu, Qi Zhang, Zhong Li

引用次数: 0